홈 > 시장보고서 > 의약품 > 신약개발

시장보고서

상품코드

1571364

임상시험 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 임상시험 설계별, 적응증별, 단계별, 지역별

Clinical Trials Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Study Design, Indications, Phase Type, and Geography

발행일: 2024년 09월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 211 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

임상시험 시장은 2023년 433억 7,000만 달러에서 2031년 733억 3,000만 달러로 성장하여 2023-2031년 연평균 6.8%의 성장률을 기록할 것으로 예측됩니다. 임상시험 수가 크게 증가함에 따라 임상시험 아웃소싱 관행이 확산되고 연구개발 활동이 급증하면서 제약 업계의 번영이 임상시험 시장 성장에 기여하고 있습니다. 그러나 임상시험은 비용과 시간이 많이 소요되기 때문에 시장 성장을 저해하는 요인으로 작용하고 있습니다. 또한, AI를 활용한 임상시험은 향후 몇 년 동안 새로운 임상시험 시장 동향을 가져올 것으로 예상됩니다.

임상시험은 사람을 대상으로 의학, 외과적 또는 행동학적 개입을 시험하는 조사 연구입니다. 이러한 임상시험은 신약, 식이요법, 의료기기(예: 심박조율기)와 같은 새로운 치료법이나 예방법이 사람들에게 안전하고 효과적인지 여부를 연구자들이 판단하기 위한 1차 연구입니다. 대부분의 경우, 임상시험은 새로운 치료법이 기존 치료법보다 더 효과적인지 또는 부작용이 적은지 알아보기 위해 실시됩니다.

2023년 세계 임상시험 시장에서 북미가 가장 큰 비중을 차지했습니다. 북미 임상시험 시장은 미국, 캐나다, 멕시코로 구분됩니다. 미국은 주요 임상 연구 대상국입니다. 임상시험의 절반 가까이가 미국에서 실시되고 있습니다. 또한, 잘 구축된 의료 인프라, 신속한 승인 일정, 유리한 규제 프레임워크, 세계적으로 인정받는 임상시험 생성 데이터 등의 이유로 대부분의 제약 연구 회사들은 미국에서 임상시험 수행을 선호합니다. 세계보건기구(WHO) 보고서에 따르면 2021년 미국의 임상시험 건수가 가장 많아 15만7618건에 달했습니다.

미국 임상시험 시장의 성장은 기업들이 임상시험에 적용하기 위해 출시한 혁신적인 제품에 기인합니다. 임상시험을 위한 다양한 서비스를 제공하는 임상연구기관(CRO)인 메디컬 메트릭스는 "Assessa"를 제공하고 있습니다. 이 제품은 신약개발 및 관련 임상시험의 의사결정 과정을 지원합니다. 치매, 인지기능장애, 알츠하이머병, 파킨슨병, 정신분열증, 기타 기억력 관련 질환 등 신경질환에 대한 약물 발견을 돕습니다. 미국에서는 임상시험 건수가 증가하고 있으며, 이는 미국 임상시험 시장의 성장에 유리합니다.

분산형 임상시험과 하이브리드형 임상시험의 채택이 향후 시장 기회를 가져다 줄 것이다

분산형 임상시험(DCT)에 등록한 피험자는 병원 내 임상시험 시설에 자주 방문할 필요가 없으며, DCT는 디지털 기술을 사용하여 임상 연구를 위한 환자 접근, 원격 데이터 수집 및 모니터링, 연구자와 피험자 간의 커뮤니케이션을 가능하게 합니다. 디지털 기술을 사용합니다. 재택 및 현장 활동을 결합하여 최고의 환자 경험을 제공하고 복잡한 프로토콜 요법을 충족시키는 하이브리드 임상시험 접근 방식은 다양한 치료 영역과 임상시험 단계에서 지지를 얻고 있습니다. 당초 DCT의 채택은 환자 프라이버시, 데이터 보안, 규제 장벽, 복잡한 프로토콜 체계 등의 문제로 인해 영향을 받았습니다. 그러나 COVID-19 팬데믹으로 인해 대면 임상시험이 불가능해지면서 임상시험 스폰서들이 의약품 개발을 위해 분산형 하이브리드 임상 기술을 채택할 수밖에 없었습니다. 출퇴근이 제한되는 상황에서 데이터를 수집하고 임상시험을 지속할 수 있는 유일한 방법은 원격으로 작업하고 기술을 최적으로 활용하여 프로세스를 가속화하는 것이었습니다. McKinsey가 제공한 데이터에 따르면, 임상시험의 잠재적 참가자의 -70%가 시험 수행 시설에서 멀리 떨어져 있습니다. 따라서 분산화를 통해 임상시험에 대한 접근성을 넓혀 더 많은 피험자, 잠재적으로 더 다양한 환자 풀에 도달 할 수 있습니다.

하이브리드 임상시험을 통해 임상시험 의뢰자는 임상시험 설계에 DCT 요소를 전략적으로 통합할 수 있습니다. ObvioHealth에 따르면, FDA는 향후 임상 연구의 신뢰성을 높이기 위해 2023년에 DCT 방법의 사용을 지원하는 프로토콜을 발표할 계획이었다고 합니다. 프로토콜을 발표할 계획을 가지고 있었습니다. 이처럼 기존 임상시험 방식보다 분산형 임상시험과 하이브리드 임상시험의 활용에 대한 관심이 높아지면서 예측 기간 동안 임상시험 시장에 유리한 기회를 제공할 것으로 예상됩니다.

시험 설계에 기반한 인사이트

시험 설계에 따라 시장은 중재 시험과 확대 접근 시험으로 나뉩니다.

적응증에 기반한 인사이트

적응증별로는 심혈관질환, 암, 신경질환, 자가면역질환/염증, 통증관리, 당뇨병, 비만, 대사성질환, 기타로 구분됩니다.

단계에 따른 인사이트

단계별로 임상시험 시장은 1단계, 2단계, 3단계로 나뉩니다.

임상시험 시장 경쟁 상황 및 주요 발전 상황

IQVIA Holdings Inc, Parexel International Corporation, IXICO Plc, Charles River Laboratories Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, SIRO Clinpharm Private Limited, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx, Caidya, Oracle Corp, Medpace Medpace 등이 임상시험 시장에서 사업을 전개하는 주요 기업들입니다.

미국 식품의약국, 미국 질병통제예방센터(CDC), 세계질병부담조사(WCDC)는 임상시험 시장 보고서를 작성할 때 참고한 1차 정보 및 2차 정보 중 하나입니다.

임상시험 시장 - 주요 시장 역학
시장 성장 촉진요인
- 임상시험 수 급증에 따른 임상시험 아웃소싱화
- 연구개발 활동 급증에 따른 제약 업계 번영
시장 성장 억제요인
- 고가이고 시간이 걸리는 프로세스
시장 기회
- 분산형 임상시험과 하이브리드 임상시험 채용
향후 동향
- AI 주도형 임상시험
성장 촉진요인과 억제요인의 영향

제6장 임상시험 시장 - 세계 시장 분석

임상시험 시장 매출, 2021-2031년
세계의 임상시험 시장 예측 분석

제7장 임상시험 시장 : 시험 설계별

개입 시험
확장 액세스 시험

제8장 임상시험 시장 : 적응증별

자가면역질환/염증
통증 관리
종양 질환
신경질환
당뇨병
비만
대사질환
심혈관질환
기타

제9장 임상시험 시장 : 단계별

단계 I
단계 II
단계 III

제10장 임상시험 시장 : 지역별

북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 스페인
- 이탈리아
- 폴란드
- 스위스
- 스웨덴
- 덴마크
- 벨기에
- 네덜란드
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 인도네시아
- 말레이시아
- 싱가포르
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 업계 상황

임상시험 시장의 성장 전략
유기적 성장 전략
무기적 성장 전략

제12장 기업 개요

QVIA Holdings Inc
Parexel International Corp
IXICO Plc
Charles River Laboratories International Inc
ICON Plc
WuXi AppTec Co Ltd
SGS SA
Syneos Health Inc
SIRO Clinpharm Pvt Ltd
Thermo Fisher Scientific Inc
Laboratory Corp of America Holdings
CliniRx Research Private Limited
Caidya
Oracle Corp
Medpace Holdings Inc

제13장 부록

ksm 24.10.25

The clinical trials market is anticipated to grow from US$ 43.37 billion in 2023 and is projected to reach US$ 73.33 billion by 2031; it is expected to register a CAGR of 6.8% during 2023-2031. The practice of outsourcing clinical studies with a massive rise in the number of trials and the flourishing pharmaceutical industry with a surge in R&D activities are contributing to the clinical trials market growth. However, the expensive and time-consuming nature of trials hampers market growth. Further, AI-driven clinical trials are expected to bring new clinical trials market trends in the coming years.

Clinical trials are research studies that test a medical, surgical, or behavioral intervention in people. These trials are the primary way that researchers determine if a new form of treatment or prevention, such as a new drug, diet, or medical device (for example, a pacemaker), is safe and effective in people. Often, a clinical trial is designed to learn if a new treatment is more effective or has less harmful side effects than existing treatments.

North America accounted for a major share of the global clinical trials market in 2023. The clinical trials market in North America is segmented into the US, Canada, and Mexico. The US has become a leading clinical research destination. Nearly half of the clinical trials are conducted in the US. Additionally, most pharmaceutical research companies prefer to conduct clinical trials in the US due to established medical infrastructure, rapid approval timelines, a favorable regulatory framework, and accepted clinical trial-generated data globally. A World Health Organization (WHO) report states that the US had the highest number of clinical trials, with 157,618 trials in 2021.

The growth of the clinical trials market in the US can be attributed to innovative products launched by companies for applications in clinical trials. Medical Metrics, a clinical research organization (CRO) providing various services for clinical trials, offers "Assessa." This product assists in the decision-making process of drug discovery and related clinical studies. It helps discover drugs for neurological disorders, such as dementia, cognitive impairment, Alzheimer's disease, Parkinson's Disease, Schizophrenia, and other memory-related diseases. The rising number of clinical trials in the US favors the growth of the clinical trials market in the country.

Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials to Provide Market Opportunities in Future

Subjects enrolled in decentralized clinical trials (DCT) do not need to access hospital-based trial sites frequently. In DCTs, digital technologies are used to enable access of patients for clinical research, remote data collection and monitoring, and communication between investigators and participants. A hybrid clinical trial approach combines home-based and on-site activities, bringing the best patient experience and meeting complex protocol regimes, gaining traction across various therapeutic areas and trial phase journeys. Initially, the adoption of DCT was affected due to challenges such as patient privacy, data security, regulatory barriers, and complex protocol regimes. However, the COVID-19 pandemic compelled the sponsors of clinical trials to adopt decentralized and hybrid clinical techniques for developing drugs, as in-person studies were not feasible amid this health crisis. With restrictions imposed on commute, the only way to gather data and keep trials going was to work remotely and make optimal use of technologies to accelerate processes. According to the data provided by McKinsey, ~70% of the potential participants for clinical trials stay away from trial sites. Therefore, decentralization broadens trial access to reach a larger number of subjects, consisting of potentially a more diverse pool of patients.

Hybrid clinical trials allow sponsors to strategically incorporate DCT elements into study designs. These trial models offer unprecedented flexibility; thus, more companies are showing interest in hybrid trials, which is redefining the industry landscape. According to ObvioHealth, the FDA had plans to unveil protocols to support the use of DCT methods in 2023 to enhance the credibility of future clinical research. Thus, the increasing focus on using decentralized and hybrid clinical trials over traditional clinical trial methods is expected to provide lucrative opportunities for the clinical trials market during the forecast period.

Study Design -Based Insights

Based on study design, the market is bifurcated into interventional trials and expanded access trials.

Indication -Based Insights

By indication, the market is segmented into cardiovascular diseases, oncological conditions, neurological disorders, autoimmune diseases/inflammation, pain management, diabetes, obesity, metabolic disorders, and others.

Phase -Based Insights

Based on phase, the clinical trials market is divided into Phase I, Phase II, and Phase III.

Clinical Trials Market: Competitive Landscape and Key Developments

IQVIA Holdings Inc, Parexel International Corporation, IXICO Plc, Charles River Laboratories Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, SIRO Clinpharm Private Limited, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx, Caidya, Oracle Corp, and Medpace are among the key companies operating in the clinical trials market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the clinical trials market report.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Clinical Trials Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Clinical Trials Market - Key Market Dynamics

5.1 Clinical Trials Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Practice of Outsourcing Clinical Studies with Massive Rise in Number of Trials
- 5.2.2 Flourishing Pharmaceutical Industry with Surge in R&D Activities
5.3 Market Restraints
- 5.3.1 Expensive and Time-Consuming Process
5.4 Market Opportunities
- 5.4.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
5.5 Future Trends
- 5.5.1 AI-Driven Clinical Trials
5.6 Impact of Drivers and Restraints:

6. Clinical Trials Market - Global Market Analysis

6.1 Clinical Trials Market Revenue (US$ Million), 2021-2031
6.2 Global Clinical Trials Market Forecast Analysis

7. Clinical Trials Market Analysis - by Study Design

7.1 Interventional Trials
- 7.1.1 Overview
- 7.1.2 Interventional Trials: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Expanded Access Trials
- 7.2.1 Overview
- 7.2.2 Expanded Access Trials: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)

8. Clinical Trials Market Analysis - by Indications

8.1 Autoimmune Diseases/Inflammation
- 8.1.1 Overview
- 8.1.2 Autoimmune Diseases/Inflammation : Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Pain Management
- 8.2.1 Overview
- 8.2.2 Pain Management: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Oncological Conditions
- 8.3.1 Overview
- 8.3.2 Oncological Conditions: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Neurological Disorders
- 8.4.1 Overview
- 8.4.2 Neurological Disorders: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Diabetes
- 8.5.1 Overview
- 8.5.2 Diabetes: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Obesity
- 8.6.1 Overview
- 8.6.2 Obesity: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Metabolic Disorders
- 8.7.1 Overview
- 8.7.2 Metabolic Disorders: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Cardiovascular Diseases
- 8.8.1 Overview
- 8.8.2 Cardiovascular Diseases: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
8.9 Others
- 8.9.1 Overview
- 8.9.2 Others: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)

9. Clinical Trials Market Analysis - by Phase

9.1 Phase I
- 9.1.1 Overview
- 9.1.2 Phase I: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Phase II
- 9.2.1 Overview
- 9.2.2 Phase II: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Phase III
- 9.3.1 Overview
- 9.3.2 Phase III: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)

10. Clinical Trials Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Clinical Trials Market Overview
- 10.2.2 North America: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  - 10.2.2.1 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
  - 10.2.2.2 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
  - 10.2.2.3 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
- 10.2.3 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 United States: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.3.1.1 United States: Clinical Trials Market Breakdown, by Study Design
    - 10.2.3.1.2 United States: Clinical Trials Market Breakdown, by Indications
    - 10.2.3.1.3 United States: Clinical Trials Market Breakdown, by Phase
  - 10.2.3.2 Canada: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.3.2.1 Canada: Clinical Trials Market Breakdown, by Study Design
    - 10.2.3.2.2 Canada: Clinical Trials Market Breakdown, by Indications
    - 10.2.3.2.3 Canada: Clinical Trials Market Breakdown, by Phase
  - 10.2.3.3 Mexico: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.3.3.1 Mexico: Clinical Trials Market Breakdown, by Study Design
    - 10.2.3.3.2 Mexico: Clinical Trials Market Breakdown, by Indications
    - 10.2.3.3.3 Mexico: Clinical Trials Market Breakdown, by Phase
10.3 Europe
- 10.3.1 Europe Clinical Trials Market Overview
- 10.3.2 Europe: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  - 10.3.2.1 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
  - 10.3.2.2 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
  - 10.3.2.3 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
- 10.3.3 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 United Kingdom: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.1.1 United Kingdom: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.1.2 United Kingdom: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.1.3 United Kingdom: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.2 Germany: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.2.1 Germany: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.2.2 Germany: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.2.3 Germany: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.3 France: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.3.1 France: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.3.2 France: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.3.3 France: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.4 Spain: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.4.1 Spain: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.4.2 Spain: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.4.3 Spain: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.5 Italy: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.5.1 Italy: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.5.2 Italy: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.5.3 Italy: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.6 Poland: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.6.1 Poland: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.6.2 Poland: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.6.3 Poland: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.7 Switzerland: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.7.1 Switzerland: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.7.2 Switzerland: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.7.3 Switzerland: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.8 Sweden: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.8.1 Sweden: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.8.2 Sweden: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.8.3 Sweden: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.9 Denmark: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.9.1 Denmark: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.9.2 Denmark: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.9.3 Denmark: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.10 Belgium: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.10.1 Belgium: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.10.2 Belgium: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.10.3 Belgium: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.11 Netherlands: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.11.1 Netherlands: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.11.2 Netherlands: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.11.3 Netherlands: Clinical Trials Market Breakdown, by Phase
  - 10.3.3.12 Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.3.12.1 Rest of Europe: Clinical Trials Market Breakdown, by Study Design
    - 10.3.3.12.2 Rest of Europe: Clinical Trials Market Breakdown, by Indications
    - 10.3.3.12.3 Rest of Europe: Clinical Trials Market Breakdown, by Phase
10.4 Asia Pacific
- 10.4.1 Asia Pacific Clinical Trials Market Overview
- 10.4.2 Asia Pacific: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  - 10.4.2.1 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
  - 10.4.2.2 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
  - 10.4.2.3 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
- 10.4.3 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 China: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.1.1 China: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.1.2 China: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.1.3 China: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.2 Japan: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.2.1 Japan: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.2.2 Japan: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.2.3 Japan: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.3 India: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.3.1 India: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.3.2 India: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.3.3 India: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.4 Australia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.4.1 Australia: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.4.2 Australia: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.4.3 Australia: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.5 South Korea: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.5.1 South Korea: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.5.2 South Korea: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.5.3 South Korea: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.6 Indonesia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.6.1 Indonesia: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.6.2 Indonesia: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.6.3 Indonesia: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.7 Malaysia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.7.1 Malaysia: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.7.2 Malaysia: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.7.3 Malaysia: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.8 Singapore: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.8.1 Singapore: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.8.2 Singapore: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.8.3 Singapore: Clinical Trials Market Breakdown, by Phase
  - 10.4.3.9 Rest of APAC: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.3.9.1 Rest of APAC: Clinical Trials Market Breakdown, by Study Design
    - 10.4.3.9.2 Rest of APAC: Clinical Trials Market Breakdown, by Indications
    - 10.4.3.9.3 Rest of APAC: Clinical Trials Market Breakdown, by Phase
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Clinical Trials Market Overview
- 10.5.2 Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  - 10.5.2.1 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
  - 10.5.2.2 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
  - 10.5.2.3 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
- 10.5.3 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Saudi Arabia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.3.1.1 Saudi Arabia: Clinical Trials Market Breakdown, by Study Design
    - 10.5.3.1.2 Saudi Arabia: Clinical Trials Market Breakdown, by Indications
    - 10.5.3.1.3 Saudi Arabia: Clinical Trials Market Breakdown, by Phase
  - 10.5.3.2 South Africa: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.3.2.1 South Africa: Clinical Trials Market Breakdown, by Study Design
    - 10.5.3.2.2 South Africa: Clinical Trials Market Breakdown, by Indications
    - 10.5.3.2.3 South Africa: Clinical Trials Market Breakdown, by Phase
  - 10.5.3.3 United Arab Emirates: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.3.3.1 United Arab Emirates: Clinical Trials Market Breakdown, by Study Design
    - 10.5.3.3.2 United Arab Emirates: Clinical Trials Market Breakdown, by Indications
    - 10.5.3.3.3 United Arab Emirates: Clinical Trials Market Breakdown, by Phase
  - 10.5.3.4 Rest of Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.3.4.1 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Study Design
    - 10.5.3.4.2 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Indications
    - 10.5.3.4.3 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Phase
10.6 South and Central America
- 10.6.1 South and Central America Clinical Trials Market Overview
- 10.6.2 South and Central America: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  - 10.6.2.1 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
  - 10.6.2.2 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
  - 10.6.2.3 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
- 10.6.3 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Country
  - 10.6.3.1 Brazil: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.3.1.1 Brazil: Clinical Trials Market Breakdown, by Study Design
    - 10.6.3.1.2 Brazil: Clinical Trials Market Breakdown, by Indications
    - 10.6.3.1.3 Brazil: Clinical Trials Market Breakdown, by Phase
  - 10.6.3.2 Argentina: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.3.2.1 Argentina: Clinical Trials Market Breakdown, by Study Design
    - 10.6.3.2.2 Argentina: Clinical Trials Market Breakdown, by Indications
    - 10.6.3.2.3 Argentina: Clinical Trials Market Breakdown, by Phase
  - 10.6.3.3 Rest of South and Central America: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.3.3.1 Rest of South and Central America: Clinical Trials Market Breakdown, by Study Design
    - 10.6.3.3.2 Rest of South and Central America: Clinical Trials Market Breakdown, by Indications
    - 10.6.3.3.3 Rest of South and Central America: Clinical Trials Market Breakdown, by Phase

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Clinical Trials Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 QVIA Holdings Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Parexel International Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 IXICO Plc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Charles River Laboratories International Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 ICON Plc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 WuXi AppTec Co Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 SGS SA
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Syneos Health Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 SIRO Clinpharm Pvt Ltd
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Thermo Fisher Scientific Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Laboratory Corp of America Holdings
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments
12.12 CliniRx Research Private Limited
- 12.12.1 Key Facts
- 12.12.2 Business Description
- 12.12.3 Products and Services
- 12.12.4 Financial Overview
- 12.12.5 SWOT Analysis
- 12.12.6 Key Developments
12.13 Caidya
- 12.13.1 Key Facts
- 12.13.2 Business Description
- 12.13.3 Products and Services
- 12.13.4 Financial Overview
- 12.13.5 SWOT Analysis
- 12.13.6 Key Developments
12.14 Oracle Corp
- 12.14.1 Key Facts
- 12.14.2 Business Description
- 12.14.3 Products and Services
- 12.14.4 Financial Overview
- 12.14.5 SWOT Analysis
- 12.14.6 Key Developments
12.15 Medpace Holdings Inc
- 12.15.1 Key Facts
- 12.15.2 Business Description
- 12.15.3 Products and Services
- 12.15.4 Financial Overview
- 12.15.5 SWOT Analysis
- 12.15.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,314,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,450

￦ 9,153,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 11,991,000

※ 부가세 별도